How does physical stability differ from chemical stability?

Chemical instability changes the drug molecule itself (for example by hydrolysis or oxidation), whereas physical instability leaves the molecule intact but changes its physical state, distribution, or appearance — such as a polymorphic transformation, crystallization of an amorphous drug, or phase separation.

Why is the amorphous form a physical-stability concern?

The amorphous form is higher in energy and can improve solubility, but for the same reason it tends to crystallize over time, which can erode that advantage; controlling molecular mobility and moisture is central to keeping it stable.

Physical Stability and Appearance

Physical stability concerns changes in a medicine in which the drug molecule remains chemically intact but its physical state, distribution, or appearance shifts — for example a change in crystal form, crystallization of an amorphous drug, moisture uptake, phase separation of an emulsion, or a change in colour, hardness, or dissolution. Such changes can alter performance and acceptability even when assay potency is unchanged.

Definition

Physical stability is the capacity of a pharmaceutical product to retain its physical properties — solid-state form, particle and phase distribution, appearance, and physical performance such as dissolution — over time, without change to the chemical identity of the drug.

Scope

The topic covers solid-state form changes (polymorphic transformation, crystallization of amorphous material), physical changes in dispersed and liquid systems, moisture- and temperature-driven effects, and visible appearance attributes. It is treated as physical-pharmaceutics knowledge, not clinical guidance.

Core questions

Which physical changes can occur in a formulation without altering the drug molecule, and what triggers them?
How do solid-state form and amorphous-to-crystalline transitions affect performance such as dissolution?
Which appearance and physical-performance attributes must be monitored and controlled?

Key concepts

Polymorphism and polymorphic transformation
Amorphous form and crystallization
Glass transition and molecular mobility
Moisture sorption and deliquescence
Phase separation in emulsions and suspensions
Appearance attributes (colour, caking, hardness)
Dissolution and disintegration changes

Mechanisms

A drug can be physically unstable while remaining chemically intact. Crystalline drugs may convert between polymorphic forms of different energy, altering solubility and dissolution. Amorphous drugs, which are higher in energy and often used to improve solubility, tend to crystallize over time as molecular mobility allows reordering, a process governed in part by the glass transition temperature and by plasticising moisture. Liquid and semisolid systems can show phase separation, sedimentation, or caking, and solids can take up moisture and change in colour or mechanical strength. Because these changes affect performance and appearance, they are monitored alongside chemical assay in stability programmes.

Clinical relevance

Physical changes such as a shift in crystal form or loss of an amorphous advantage can change how fast a drug dissolves and is released, and visible changes affect acceptability. Understanding physical stability explains why certain formulations require particular storage and packaging. It describes determinants of product performance over time and is not a basis for individual treatment decisions.

Evidence & guidelines

Physical attributes — appearance, dissolution, and where relevant solid-state form — are part of the specification monitored under ICH Q1 stability protocols. Strategies to stabilise high-energy amorphous systems, such as solid dispersions in polymer carriers, are an active formulation-science approach to maintaining physical stability.

History

As solid-state pharmaceutics matured, polymorphism and the behaviour of amorphous materials became recognised as central to physical stability, with the glass transition and molecular mobility providing a framework for predicting crystallization. The growing use of amorphous solid dispersions to enhance solubility sharpened interest in keeping high-energy forms physically stable over a product's shelf-life.

Key figures

Sumie Yoshioka
Valentino J. Stella
Kenneth C. Waterman

Seminal works

yoshioka-stella-2002
cao-2017

Frequently asked questions

How does physical stability differ from chemical stability?: Chemical instability changes the drug molecule itself (for example by hydrolysis or oxidation), whereas physical instability leaves the molecule intact but changes its physical state, distribution, or appearance — such as a polymorphic transformation, crystallization of an amorphous drug, or phase separation.
Why is the amorphous form a physical-stability concern?: The amorphous form is higher in energy and can improve solubility, but for the same reason it tends to crystallize over time, which can erode that advantage; controlling molecular mobility and moisture is central to keeping it stable.